Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 6, 2002
Recent advances in multiple myeloma immunotherapyP A Ruffini, A Biragyn, L W KwakCancer Immunology, Immunotherapy : CII|June 1, 1993
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cellsP A Ruffini, L Rivoltini, A Silvani, et al.Bone Marrow Transplantation|November 16, 2004
Cardiac toxicity of high-dose chemotherapyP Morandi, P A Ruffini, G M Benvenuto, et al.Bone Marrow Transplantation|September 6, 2001
Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamideP Morandi, P A Ruffini, G M Benvenuto, et al.Cancer Immunology, Immunotherapy : CII|September 1, 1994
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patientsA Boiardi, A Silvani, P A Ruffini, et al.British Journal of Haematology|September 1, 1996
Combined negative and positive selection of mobilized CD34 blood cellsM Di Nicola, M Bregni, S Siena, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2001
Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigensA Biragyn, M Surenhu, D Yang, et al.Bone Marrow Transplantation|September 1, 1996
Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substituteM Di Nicola, S Siena, M Bregni, et al.British Journal of Cancer|October 1, 1995
In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibodyD R Negri, E Tosi, O Valota, et al.Pageof 2